Jardiance Pipeline and Next-Gen: What's Ahead for Empagliflozin

Regulatory Timeline: From First Approval to Label Expansions

Empagliflozin received its initial FDA approval on August 1, 2014, as a 10 mg and 25 mg oral tablet for glycemic control in adults with type 2 diabetes mellitus [1]. The approval was based on Phase III data from the EMPA-REG H2H-SU trial and pooled key studies showing HbA1c reductions of 0.7% to 0.8% versus placebo at 24 weeks [2].

The EMPA-REG OUTCOME Milestone

The drug's trajectory changed in 2015 when the EMPA-REG OUTCOME trial (N=7,020) reported a 14% reduction in major adverse cardiovascular events (MACE) and a 38% relative risk reduction in cardiovascular death among patients with type 2 diabetes and established cardiovascular disease [3]. No other glucose-lowering agent had demonstrated a mortality benefit of that magnitude in a dedicated outcomes trial at the time.

Cardiovascular and Heart Failure Expansions

In December 2016, FDA updated the Jardiance label to include a cardiovascular death reduction indication, making it the first type 2 diabetes drug approved specifically for this purpose [4]. The EMPEROR-Reduced trial (N=3,730) then demonstrated a 25% reduction in the composite of cardiovascular death or heart failure hospitalization in patients with heart failure and reduced ejection fraction (HFrEF), regardless of diabetes status [5]. FDA granted the heart failure indication in August 2021 for HFrEF.

By February 2022, results from EMPEROR-Preserved (N=5,988) extended the approval to heart failure with preserved ejection fraction (HFpEF), a condition that had resisted pharmacologic intervention for decades [6]. Dr. Milton Packer, who served on the EMPEROR steering committee, noted: "This is the first drug class to show consistent benefit across the entire ejection-fraction spectrum in heart failure."

The CKD Data Package

The EMPA-KIDNEY trial (N=6,609), published in The Lancet in 2023, showed empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72; 95% CI 0.64 to 0.82; P<0.001) in patients with chronic kidney disease, including those without diabetes [7]. A supplemental new drug application (sNDA) for CKD was submitted to FDA, and the indication remains under review.

Current FDA-Approved Indications and Formulations

The Jardiance label now covers three distinct clinical indications, each backed by dedicated outcomes trials. The prescribing information runs 38 pages and includes five sections of warnings and precautions [8].

Approved Uses

Type 2 diabetes: as an adjunct to diet and exercise for glycemic improvement in adults. Cardiovascular risk reduction: to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. Heart failure: to reduce the risk of cardiovascular death and hospitalization in adults with heart failure, regardless of ejection fraction or diabetes status.

Available Formulations

Jardiance is available as 10 mg and 25 mg tablets. Synjardy and Synjardy XR combine empagliflozin (5 mg, 10 mg, 12.5 mg, or 25 mg) with metformin (500 mg, 850 mg, or 1,000 mg) in immediate- and extended-release forms [9]. Boehringer Ingelheim also markets Glyxambi, a fixed-dose tablet pairing empagliflozin 10 mg or 25 mg with linagliptin 5 mg (a DPP-4 inhibitor), approved for type 2 diabetes [10].

Dosing and Label Details

For type 2 diabetes, the label recommends starting at 10 mg once daily in the morning, with an option to increase to 25 mg. For heart failure, 10 mg once daily is the approved dose. Renal thresholds differ by indication: glycemic efficacy is limited below eGFR 30 mL/min/1.73 m², but the heart failure and cardiovascular indications have no lower eGFR cutoff in the current label [8].

Post-Market Safety Profile

A drug's real-world safety picture emerges after millions of patient-years of exposure. Empagliflozin's post-market record includes both reassuring signals and specific risks that have prompted label revisions.

Established Safety Signals

FDA issued a Drug Safety Communication in August 2015 warning that SGLT2 inhibitors, including empagliflozin, may cause diabetic ketoacidosis (DKA), sometimes presenting with only modestly elevated blood glucose [11]. A second communication in 2018 added warnings for Fournier gangrene (necrotizing fasciitis of the perineum), a rare but serious complication reported in 55 cases across all SGLT2 inhibitors between 2013 and 2019 [12].

Genitourinary Infections and Amputations

Genital mycotic infections occur in approximately 5%, 6% of female patients and 3%, 4% of male patients on empagliflozin, compared with <1% on placebo [3]. Unlike canagliflozin, empagliflozin has not shown a statistically significant increase in lower-limb amputations in any completed outcomes trial, and the FDA did not apply the amputation warning to the Jardiance label [13].

Volume Depletion and Hypotension

Osmotic diuresis from glycosuria can cause intravascular volume depletion, particularly in elderly patients, those on loop diuretics, or patients with eGFR <45. The label recommends assessing volume status before initiation and monitoring for signs of hypotension [8]. In EMPA-REG OUTCOME, volume depletion events occurred in 5.1% of the empagliflozin group versus 4.2% of placebo [3].

Active Pipeline Expansions for Empagliflozin

Boehringer Ingelheim and Lilly are pursuing several regulatory submissions and clinical programs to broaden empagliflozin's approved uses beyond the current label.

Chronic Kidney Disease

The EMPA-KIDNEY sNDA represents the most advanced pipeline item. If approved, empagliflozin would join dapagliflozin (Farxiga) as the second SGLT2 inhibitor with a standalone CKD indication. Dapagliflozin's CKD approval in April 2021, based on the DAPA-CKD trial (N=4,304), showed a 39% reduction in the composite kidney endpoint [14]. The EMPA-KIDNEY data showed consistent benefits across eGFR subgroups, including patients with eGFR 20 to 45 mL/min/1.73 m² [7].

Pediatric and Adolescent Populations

A Phase III trial (DINAMO, NCT03429543) evaluated empagliflozin in children and adolescents aged 10 to 17 with type 2 diabetes. Results showed HbA1c reductions of 0.2% with empagliflozin 10 mg and 0.7% with 25 mg versus an increase of 0.7% in the placebo arm at 26 weeks [15]. A pediatric supplemental application has been filed. If approved, Jardiance would become available for adolescents, a population with limited FDA-approved glucose-lowering options beyond metformin and insulin.

Combination Approaches

Boehringer Ingelheim is investigating BI 456906, a glucagon/GLP-1 receptor dual agonist, in Phase II/III trials for obesity and MASH (metabolic dysfunction-associated steatohepatitis). While not empagliflozin itself, the compound could eventually be co-prescribed or combined with SGLT2 inhibitors for cardiometabolic multimorbidity [16].

Next-Generation SGLT Inhibitors and Competitive Field

The SGLT2 class is no longer novel, and several next-generation molecules aim to improve on the selectivity, renal protection, or mechanism breadth of current agents.

SGLT1/2 Dual Inhibitors

Sotagliflozin, developed by Lexicon Pharmaceuticals, inhibits both SGLT1 (intestinal glucose absorption) and SGLT2 (renal glucose reabsorption). The SOLOIST-WHF trial (N=1,222) demonstrated a 33% reduction in cardiovascular deaths and heart failure events in patients with diabetes and recent worsening heart failure [17]. FDA approved sotagliflozin (Inpefa) in May 2023 for heart failure, making it the first dual SGLT1/2 inhibitor on the U.S. Market.

The dual mechanism offers a theoretical advantage: reducing postprandial glucose spikes via intestinal SGLT1 blockade while maintaining renal glycosuria through SGLT2 inhibition. Gastrointestinal side effects (diarrhea in 8%, 10% of patients) remain a differentiating concern [17].

SGLT2 + GLP-1 Fixed-Dose Combinations

The most closely watched pipeline trend is fixed-dose oral combinations pairing SGLT2 inhibitors with GLP-1 receptor agonists. Dr. Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow, has stated: "Combining SGLT2 inhibition with GLP-1 agonism in a single tablet could simplify treatment of cardiometabolic disease the way statins simplified lipid management."

Multiple pharmaceutical companies have disclosed early-stage programs exploring oral semaglutide or orforglipron combined with empagliflozin or dapagliflozin, though none has reached Phase III as of May 2026.

Emerging Targets Beyond SGLT

Ketohexokinase (KHK) inhibitors, which block fructose metabolism in the liver, represent a mechanistically distinct approach to MASH and metabolic disease. Johnson & Johnson's KHK inhibitor (JNJ-0860) entered Phase II trials in 2025 [18]. These agents do not directly compete with empagliflozin but could complement it in combination regimens for patients with type 2 diabetes, heart failure, and liver fibrosis.

How Empagliflozin Fits Into Current Guidelines

Multiple specialty societies now position SGLT2 inhibitors, including empagliflozin, as first-line or preferred agents in specific clinical scenarios.

Diabetes Guidelines

The 2024 American Diabetes Association (ADA) Standards of Care recommend SGLT2 inhibitors as preferred second-line agents (after metformin) for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, heart failure, or CKD with albuminuria [19]. The guidelines note that the cardiovascular and renal benefits of empagliflozin and dapagliflozin are independent of glucose-lowering effect.

Heart Failure Guidelines

The 2022 AHA/ACC/HFSA guideline for heart failure management gives a Class I recommendation (Level of Evidence A) for SGLT2 inhibitors in patients with HFrEF (EF ≤40%), and a Class IIa recommendation for HFpEF (EF >40%) [20]. Empagliflozin and dapagliflozin are the two agents named in the recommendation.

Kidney Disease Guidelines

KDIGO 2024 guidelines recommend SGLT2 inhibitors for patients with CKD and eGFR ≥20 mL/min/1.73 m², regardless of diabetes status, citing a consistent 30%, 40% reduction in kidney failure across trials [21]. The guideline committee acknowledged that the eGFR threshold may shift lower as more data accumulate from trials like EMPA-KIDNEY.

What Clinicians Should Watch

Three regulatory and clinical milestones will shape empagliflozin's trajectory over the next 12 to 24 months.

CKD Indication Decision

FDA action on the EMPA-KIDNEY sNDA will determine whether Jardiance competes directly with Farxiga in nephrology clinics. Label language around eGFR thresholds and albuminuria requirements will influence formulary positioning.

Pediatric Approval

An adolescent indication would address a gap in type 2 diabetes management for patients aged 10 to 17. Fewer than five non-insulin medications carry pediatric type 2 diabetes approvals in the United States.

Post-Market Surveillance Updates

FDA's Sentinel System continues to monitor SGLT2 inhibitor safety in real-world populations exceeding 10 million patient-years of cumulative exposure. Ongoing analyses focus on bone fracture risk, bladder cancer, and acute kidney injury rates across the SGLT2 class [22]. Clinicians should review the Drugs@FDA label updates quarterly for any new safety signals or indication changes tied to empagliflozin.